Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viking Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, and clinical-development disclosures for VK2735, including subcutaneous and oral obesity programs, trial results, and related regulatory communications.
The company's proxy materials disclose board and shareholder-voting matters, executive compensation, equity awards, and pay-versus-performance information. Viking's SEC record also covers Regulation FD communications, clinical-development updates, cash resources, and governance matters tied to a development-stage biotechnology issuer.
Viking Therapeutics outlines a broad late-stage pipeline for metabolic and endocrine diseases in its annual report. Lead obesity candidate VK2735, a dual GLP-1/GIP agonist, has moved into Phase 3 VANQUISH studies after Phase 2 data showed up to 14.7% mean weight loss over 13 weeks and up to 88% of patients achieving at least 10% weight reduction.
The oral tablet form of VK2735 delivered up to 12.2% weight loss versus 1.3% with placebo over 13 weeks, supporting planned Phase 3 oral studies. NASH/MASH candidate VK2809 produced robust 52‑week histology results, with NASH resolution in up to 75% of patients and ≥1‑stage fibrosis improvement in up to 57%, both outperforming placebo.
Viking also reports positive early data in rare disease program VK0214 for X‑ALD and muscle‑building agent VK5211, while securing large-scale VK2735 manufacturing through multi‑year CordenPharma agreements. As context, non‑affiliate equity was valued at $2,976,737,289 as of June 30, 2025, with 115,554,295 shares outstanding as of January 31, 2026.
Viking Therapeutics reported a much larger net loss for 2025 as it accelerated investment in its obesity pipeline, led by dual GLP‑1/GIP agonist VK2735. For 2025, the company recorded a net loss of $358.5 million, or $3.19 per share, versus a loss of $110.0 million, or $1.01 per share, in 2024. Research and development spending rose to $345.0 million from $101.6 million, reflecting extensive Phase 3 work on subcutaneous VK2735, positive Phase 2 oral VK2735 data, and broader pipeline progress. General and administrative costs were roughly flat at $48.4 million. As of December 31, 2025, Viking held $706 million in cash, cash equivalents and short‑term investments, which the company believes supports key upcoming milestones. Clinical highlights include ongoing Phase 3 VANQUISH trials for injectable VK2735 in obesity, plans to start Phase 3 for oral VK2735 in 3Q26, a fully enrolled VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an IND for a novel amylin agonist in 1Q26.
Viking Therapeutics Chief Commercial Officer Neil William Aubuchon received a grant of stock options on common stock. The award covers 180,000 stock options with an exercise price of $31.76 per share, expiring on 01/12/2036.
According to the vesting terms, 25% of the options vest immediately, and an additional 25% vest on each one-year anniversary of the grant date over the next three years. After this grant, Aubuchon directly holds 180,000 derivative securities in the form of these options.
Viking Therapeutics, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Neil William Aubuchon, on a Form 3. The filing states that, at the time of this report, he does not beneficially own any Viking Therapeutics securities, either directly or indirectly. This is a standard disclosure required when an individual becomes an officer of a public company and establishes a baseline of reported ownership going forward.
Viking Therapeutics reported insider equity activity by its Chief Operating Officer. On January 2, 2026, the officer received 41,000 restricted stock units and an additional 32,049 shares from performance-based restricted stock units, both at $0 cost, increasing beneficial ownership. On the same date, the officer was also granted a stock option for 91,000 shares at an exercise price of $35.42 per share, vesting in equal annual installments over four years. On January 5, 2026, a total of 57,661 shares were automatically sold in multiple transactions at weighted-average prices between about $31.87 and $35.20 to cover tax withholding obligations tied to these vesting awards. Following these transactions, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock.
Viking Therapeutics (VKTX) COO reported Form 4 activity. On October 27, 2025, 11,117 shares were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On October 28, 2025, 6,185 shares were sold at a weighted average price of $35.0027 to cover tax withholding related to the vesting.
Following these transactions, the executive directly beneficially owned 382,467 shares. The sales were executed in multiple trades between $34.69 and $35.40.
Viking Therapeutics (VKTX) reported insider activity by a director on 10/27/2025. The director exercised stock options for 60,000 shares in total—16,000 at an exercise price of $4.48, 22,000 at $5.80, and 22,000 at $4.88.
On the same date, the director sold 60,000 shares at a $35.5713 weighted-average price, with sales occurring between $35.02 and $35.94. Following these transactions, the director beneficially owned 30,000 shares directly.
Option origins and terms disclosed include grants dated 01/02/2019 (expiring 01/02/2028), 01/04/2022 (expiring 01/04/2031), and 01/03/2023 (expiring 01/03/2032), each corresponding to the exercised amounts listed above.
Viking Therapeutics (VKTX) President & CEO and director reported equity activity on Form 4. On 10/27/2025, 70,084 shares of common stock were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 38,989 shares were sold at a $35.0079 weighted average solely to satisfy tax withholding, with trades ranging $34.66–$35.48. Following the transactions, direct beneficial ownership stands at 2,419,109 shares.
Viking Therapeutics (VKTX) reported a Form 4 for its Chief Financial Officer. On 10/27/2025, the CFO acquired 11,117 shares of common stock at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 6,185 shares were sold at a weighted average price of $35.0009 to satisfy tax withholding related to that vesting.
Following these transactions, the CFO directly holds 173,592 shares. Shares briefly stood at 179,777 after the vesting before the tax-related sale.
Viking Therapeutics (VKTX) filed its Q3 2025 report, showing higher R&D as programs advanced and a wider loss. For the quarter, net loss was $90.8 million, or $0.81 per share, driven by research and development expense of $89.9 million and general and administrative expense of $8.6 million. There was no revenue.
Liquidity remained strong with cash and cash equivalents of $100.4 million and short‑term investments of $614.2 million as of September 30, 2025. For the nine months, the company used $193.4 million in operating cash. Stockholders’ equity was $713.0 million.
Capital markets tools are in place: an S‑3 shelf effective July 2023, ATM capacity remaining up to $151.9 million, and a $250.0 million repurchase program authorized in February 2025 (no repurchases in Q3). The March 2024 offering provided $597.1 million net proceeds. Shares outstanding were 113,036,344 as of October 15, 2025.
Operationally, Viking entered multi‑year manufacturing agreements for VK2735 with prepayments from 2025 to 2028 credited against future orders. A subsequent lease amendment expands headquarters space, with $63,000 monthly base rent starting on the later of substantial completion or April 1, 2026.